Biocon Share Price Target 2024, 2025 to 2030

0 Shares

Biocon Limited, established in 1978 by Kiran Mazumdar-Shaw, is a prominent biopharmaceutical company headquartered in Bangalore, India. With a strong global presence, Biocon produces generic active pharmaceutical ingredients (APIs) distributed in 120 countries, including major markets such as the United States and Europe. Renowned for its biosimilar insulins, antibodies, and novel biologics, Biocon addresses diverse medical needs worldwide. In India, its product portfolio includes treatments for metabolics, oncology, immunotherapy, and nephrology, featuring well-known brands like INSUGEN, BASALOG, and CANMAb. Furthermore, Biocon’s subsidiary, Syngene International Limited, operates as a contract research and development organization, bolstering the company’s research capabilities.

History of Biocon

Founded in 1978 by Kiran Mazumdar with an initial capital of merely Rs. 10,000, Biocon rapidly ascended to a preeminent position within the biopharmaceutical sector. Landmark achievements include pioneering enzyme exports to the US and Europe in 1979 and attaining USFDA approval for lovastatin production in 2001. Over the decades, strategic alliances and expansions have catalyzed Biocon’s growth, resulting in innovations such as the development of human insulin using a Pichia expression system and the introduction of BIOMAb EGFR for oncological treatment. Collaborations with global giants like Abbott and Amgen have further entrenched its status.

In 2021, Biocon Biologics forged a partnership with the Serum Institute of India to commercialize vaccines and biological drugs, significantly augmenting its public health influence. The acquisition of Viatris’ biosimilar assets in 2022 enhanced its dominance in the biosimilars market, emphasizing its commitment to advancing global healthcare. Throughout its evolution, Biocon has consistently prioritized innovation, significantly impacting the biopharmaceutical landscape and enhancing patient outcomes worldwide.

Biocon Q4 FY24 Results Highlights

Q4 FY24 saw Biocon’s consolidated net profit decline by 57% to Rs 136 crore, primarily attributed to higher expenses.
Total revenue for the fourth quarter witnessed a marginal increase to Rs 3,966 crore compared to the same period last year.
Total expenses for Q4 surged to Rs 3,635 crore, indicative of the challenging operational environment faced by the company.
Despite the Q4 setback, Biocon’s fiscal year ending March 31, 2024, showcased a substantial rise in consolidated net profit to Rs 1,022 crore compared to the previous fiscal year.
Total revenue for FY24 surged to Rs 15,621 crore, underscoring steady growth in performance across its various business segments.
A noteworthy highlight was the Biologics segment’s achievement of a billion-dollar annual revenue milestone, indicating robust growth and market demand.
The biosimilars business experienced increased market shares and significant volume growth in key regions such as the US, Europe, and emerging markets, contributing to Biocon’s positive momentum.
Strategic initiatives focused on debt reduction and long-term collaborations for product distribution in India played a pivotal role in Biocon’s transformational journey during FY24.
Reflecting its commitment to shareholders amidst challenging market conditions, the company’s board recommended a final dividend of 50 paise per share for the fiscal year.

How to Buy Biocon’s Shares in India?

To invest in Biocon shares in India, you can start by setting up a trading account with a brokerage firm. This involves providing personal information like your PAN number, bank details, and relevant identification documents. Once your account is set up, you can access the broker’s online trading platform to purchase Biocon shares.

Several online platforms facilitate share trading in India, such as Zerodha, Sharekhan, and Upstox, where you can easily buy Biocon shares and manage your investments efficiently.

Biocon’s Share Price Prediction 2024, 2025 to 2030

Biocon’s Share Price Target for 2024

When	Maximum Price	Minimum Price
May 2024	314.20	273.22
June 2024	325.52	283.06
July 2024	322.26	280.23
August 2024	335.15	291.44
September 2024	348.56	303.09
October 2024	341.72	297.15
November 2024	355.39	309.04
December 2024	358.94	312.13

Throughout 2024, Biocon’s share prices are expected to fluctuate within a dynamic market environment. Starting from May, where the shares are forecasted to range between a maximum of 314.20 and a minimum of 273.22, the trajectory continues with incremental variations each month. June sees a potential increase to a maximum of 325.52, while July maintains a similar range with a high of 322.26. As the year progresses, August marks a potential peak at 335.15, followed by September with a projected high of 348.56. October maintains stability around 341.72, yet November introduces another surge to 355.39. By December, Biocon’s shares are expected to reach a high of 358.94

Biocon Share Price Target for 2025

When	Maximum Price	Minimum Price
January 2025	362.53	278.87
February 2025	366.20	281.69
March 2025	373.89	287.61
April 2025	370.18	284.76
May 2025	359.40	276.46
June 2025	375.58	288.90
July 2025	368.21	283.24
August 2025	379.60	292.00
September 2025	384.15	295.50
October 2025	394.14	303.19
November 2025	404.00	310.77
December 2025	422.18	324.75

Throughout 2025, the trajectory of Biocon’s shares is anticipated to reflect a pattern of fluctuation and growth. Starting from January with a projected range between a maximum of 362.53 and a minimum of 278.87, the trend continues with incremental increases month by month. February sees a potential rise to a maximum of 366.20, while March maintains an upward trajectory with a high of 373.89. April maintains stability around 370.18, yet May introduces a slight decrease with a high of 359.40. As June arrives, Biocon’s shares are forecasted to climb to a maximum price of 375.58. July maintains a similar range with a high of 368.21, while August marks a potential peak at 379.60. September continues the upward trend with a projected high of 384.15. October demonstrates further growth with a high of 394.14, followed by November with a potential peak at 404.00. By December, Biocon’s shares are expected to soar to a maximum price of 422.18, showcasing significant growth throughout the year.

Biocon Share Price Target for 2026

When	Maximum Price	Minimum Price
January 2026	434.84	334.49
February 2026	423.97	326.13
March 2026	432.45	332.65
April 2026	441.28	339.44
May 2026	436.91	336.08
June 2026	447.83	344.48
July 2026	439.05	337.73
August 2026	452.63	348.17
September 2026	461.68	355.14
October 2026	473.68	364.37
November 2026	485.52	373.48
December 2026	497.66	382.82

Biocon Share Price Target for 2027

When	Maximum Price	Minimum Price
January 2027	502.64	386.65
February 2027	515.53	396.56
March 2027	535.63	412.03
April 2027	525.13	403.95
May 2027	509.84	392.18
June 2027	532.78	409.83
July 2027	522.33	401.79
August 2027	538.49	414.22
September 2027	557.33	428.72
October 2027	571.82	439.86
November 2027	586.12	450.86
December 2027	600.77	462.13

Biocon Share Price Target for 2028

When	Maximum Price	Minimum Price
January 2028	612.79	471.38
February 2028	628.50	483.46
March 2028	653.01	502.32
April 2028	640.21	492.47
May 2028	621.56	478.12
June 2028	649.53	499.64
July 2028	636.80	489.84
August 2028	656.49	504.99
September 2028	679.47	522.67
October 2028	697.13	536.26
November 2028	714.56	549.66
December 2028	732.43	563.40

Biocon Share Price Target for 2029

When	Maximum Price	Minimum Price
January 2029	747.07	574.67
February 2029	766.23	589.41
March 2029	796.11	612.39
April 2029	780.50	600.39
May 2029	757.77	582.90
June 2029	791.87	609.13
July 2029	776.34	597.19
August 2029	800.35	615.66
September 2029	828.37	637.20
October 2029	849.90	653.77
November 2029	871.15	670.12
December 2029	892.93	686.87

Biocon Share Price Target for 2030

When	Maximum Price	Minimum Price
January 2030	910.79	700.61
February 2030	934.14	718.57
March 2030	970.57	746.59
April 2030	951.54	731.96
May 2030	923.83	710.64
June 2030	965.40	742.62
July 2030	946.47	728.05
August 2030	975.74	750.57
September 2030	1,009.89	776.84
October 2030	1,036.15	797.04
November 2030	1,062.05	816.97
December 2030	1,088.61	837.39

In January 2030, Biocon’s shares are expected to range between a maximum of 910.79 and a minimum of 700.61. By December, projections indicate a potential high of 1,088.61 and a low of 837.39.

Biocon Financial Condition: Last 5 Years

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales +	6,300	7,143	8,184	11,174	14,756
Expenses +	4,725	5,562	6,391	8,762	11,541
Operating Profit	1,575	1,581	1,793	2,412	3,214
OPM %	25%	22%	22%	22%	22%
Other Income +	228	260	72	18	854
Interest	65	58	68	419	974
Depreciation	552	715	814	1,113	1,569
Profit before tax	1,186	1,068	983	897	1,525
Tax %	27%	21%	22%	28%	15%
Net Profit +	871	846	772	643	1,298
EPS in Rs	6.24	6.17	5.4	3.85	8.52
Dividend Payout %	0%	0%	9%	39%	6%

Biocon’s financial performance demonstrated a consistent upward trend from March 2020 to March 2024, with notable growth in sales and operating profit.
Sales increased steadily from ₹6,300 crore in March 2020 to ₹14,756 crore in March 2024, showcasing robust revenue growth over the four-year period.
Operating expenses also rose during this period, reaching ₹11,541 crore in March 2024, yet the company maintained a steady operating profit margin (OPM) of 22%.
Despite fluctuations in other income and an increase in interest and depreciation costs, Biocon’s profit before tax surged to ₹1,525 crore in March 2024, reflecting sustained profitability and operational efficiency.
The company’s net profit witnessed significant improvement, reaching ₹1,298 crore in March 2024, indicating effective cost management and revenue generation strategies.
Earnings per share (EPS) showed a positive trajectory, increasing from ₹6.24 in March 2020 to ₹8.52 in March 2024, signaling enhanced shareholder value and profitability.
A notable contributing factor to the higher net profit was the decreased tax rate, which stood at 15% in March 2024, providing a favorable environment for earnings growth.
However, the dividend payout ratio experienced fluctuations, peaking at 39% in March 2023 before declining to 6% in March 2024, reflecting variations in the company’s dividend distribution policies and financial priorities over the years.

Also Read

FAQs

What is the current Share Price of Biocon?

As of 18th May 2024, the current Share Price of Biocon is ₹305

Will Biocon stock price grow in 2024?

Indeed, Biocon’s stock price is poised for growth in 2024. Currently trading at approximately Rs 305, analysts project the company’s share price to rise to ₹358.94 by the conclusion of the year.

What future is anticipated for Biocon in 2025?

In the upcoming period, analysts foresee Biocon’s stock price potentially reaching Rs 422.18 by the end of 2025. The company’s steadfast commitment to innovation and quality is expected to serve as a driving force for its sustained growth in the foreseeable future.

What is the Biocon share price target for 2030?

Looking ahead to the year 2030, market projections suggest that Biocon’s stock is likely to fluctuate within a considerable range, trading between Rs 700.61 at the lower end and Rs 1,088.61 at the upper end.

Conclusion:

Biocon’s fourth-quarter results and overall financial performance underscore its resilience and potential for future growth. Despite facing a temporary dip in net profit due to heightened expenses, Biocon showcased remarkable annual revenue growth, reaching ₹15,621 crore for the fiscal year 2024. Particularly noteworthy was the milestone achievement of a billion-dollar revenue in the Biologics segment, coupled with robust market performance in key regions. Over the past five years, Biocon has consistently expanded its sales and operating profit, indicating a solid financial foundation and operational efficiency. Strategic initiatives such as debt reduction and long-term collaborations have further strengthened its market position. With an unwavering commitment to innovation and global expansion, Biocon is well-positioned for sustained growth. Its ability to navigate challenges and consistently deliver value to stakeholders underscores its potential to make a significant impact on the global healthcare landscape.

Ashnoor Khurana